Correlation Engine 2.0
Clear Search sequence regions


  • 2 3- dpg (7)
  • adults (1)
  • hemoglobin (1)
  • hemoglobin disease (1)
  • mice (3)
  • native (2)
  • oxygen (2)
  • patients (1)
  • Sizes of these terms reflect their relevance to your search.

    Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3-DPG by activation of Pyruvate Kinase-R are currently being evaluated in SCD patients. In this study, we genetically engineered a mouse lacking 2,3-DPG on the Townes SCD mouse model background and evaluated the effects of 2,3-DPG loss on disease pathology. Animals lacking 2,3-DPG showed improvements in hematological markers and reductions in RBC sickling relative to native Townes mice, however, minimal difference in organ damage was observed in 2,3-DPG deficient mice compared to native Townes animals. When animals lacking 2,3-DPG were dosed with a compound designed to increase hemoglobin oxygen affinity, oxygen delivery related toxicity was observed. © 2023 Wiley Periodicals LLC.

    Citation

    Amey Barakat, Reema Jasuja, Lindsay Tomlinson, Zane Wenzel, Lila Ramaiah, Betty A Petterson, Brendon Kapinos, Anagha Sawant, Vicente Pagan, Nathanael Lintner, Denise Field, Youngwook Ahn, Kelly M Knee. Effects of 2,3-DPG knockout on SCD phenotype in Townes SCD model mice. American journal of hematology. 2023 Sep 09


    PMID: 37688507

    View Full Text